XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Income (Loss)

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net income (loss), as presented within the table below and reconciled to the unaudited condensed consolidated statements of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis. 

		Three Months Ended September 30, 2025
		Dominari Financial				Legacy AIkido Pharma				Consolidated
Revenue		$	50,150			$	671			$	50,821
Operating Costs
Compensation and benefits			41,025				9,260				50,285
Professional and consulting fees			255				1,185				1,440
Data processing			187				-				187
Other expenses			(58	)			566				508
Income (loss) from operations			8,741				(10,340	)			(1,599	)
Other (expenses) income
Interest income			497				53				550
Gain on marketable securities			1,213				157,917				159,130
Unrealized loss on note receivable			-				-				-
Change in fair value of investments			-				(32,000	)			(32,000	)
Total other (expenses) income			1,710				125,970				127,680
Net income		$	10,451			$	115,630			$	126,081
Less: Net income attributable to non-controlling interests			871				-				871
Net income attributable to common stockholders of Dominari Holdings		$	9,580			$	115,630			$	125,210
Total assets		$	83,124			$	140,322			$	223,446

		Three Months Ended September 30, 2024
		Dominari Financial				Legacy AIkido Pharma				Consolidated
Revenue		$	3,684			$	359			$	4,043
Operating Costs
Compensation and benefits			3,798				1,613				5,411
Professional and consulting fees			232				267				499
Data processing			241				32				273
Other expenses			167				889				1,056
Loss from operations			(754	)			(2,442	)			(3,196	)
Other (expenses) income
Interest income			204				76				280
Gain on marketable securities			-				89				89
Unrealized loss on note receivable			-				(429	)			(429	)
Change in fair value of investments			-				(955	)			(955	)
Total other (expenses) income			204				(1,219	)			(1,015	)
Net loss		$	(550	)		$	(3,661	)		$	(4,211	)
Total assets		$	16,062			$	27,369			$	43,431

		Nine Months Ended September 30, 2025
		Dominari Financial				Legacy AIkido Pharma				Consolidated
Revenue		$	92,355			$	671			$	93,026
Operating Costs
Compensation and benefits			78,455				59,996				138,451
Professional and consulting fees			1,613				2,453				4,066
Data processing			546				-				546
Other expenses			675				2,323				2,998
Income (loss) from operations			11,066				(64,101	)			(53,035	)
Other (expenses) income
Interest income			878				95				973
Gain on marketable securities			4,539				158,555				163,094
Unrealized gain on note receivable			-				221				221
Change in fair value of investments			-				-				-
Total other income			5,417				158,871				164,288
Net income (loss)		$	16,483			$	94,770			$	111,253
Less: Net income attributable to noncontrolling interests			1,921				-				1,921
Net income attributable to common stockholders of Dominari Holdings		$	14,562			$	94,770			$	109,332
Total assets		$	83,124			$	140,322			$	223,446

		Nine Months Ended September 30, 2024
		Dominari Financial				Legacy AIkido Pharma				Consolidated
Revenue		$	10,553			$	1,031			$	11,584
Operating Costs
Compensation and benefits			10,037				4,210				14,247
Professional and consulting fees			993				924				1,917
Data processing			616				77				693
Other expenses			1,697				1,767				3,464
Loss from operations			(2,790	)			(5,947	)			(8,737	)
Other (expenses) income
Interest income			545				184				729
Gain on marketable securities			-				767				767
Unrealized loss on note receivable			-				(2,086	)			(2,086	)
Change in fair value of investments			-				(6,445	)			(6,445	)
Total other (expenses) income			545				(7,580	)			(7,035	)
Net loss		$	(2,245	)		$	(13,527	)		$	(15,772	)
Total assets		$	16,062			$	27,369			$	43,431

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration